Since reducing group 1 mGluR function improves multiple phenotypes in animal models of FXS, clinical trials based on mGluR5 inhibition are currently underway (Krueger and Bear, 2011) and the first results seem promising (Jacquemont et al., 2011). This evidence concerns the gene GRM5 and fragile X syndrome.